Posts

As we navigate through 2026, the AI landscape has evolved dramatically, offering data scientists an unprecedented array of powerful tools. Having worked extensively with AI-driven mathematical models in cancer research, I've witnessed firsthand how the right tools can accelerate discovery and improve outcomes. Here are the essential AI platforms and frameworks every data scientist should master this year. AutoML Platforms Have Matured Google's Vertex AI and Microsoft's Azure AutoML have transformed from experimental features into robust production systems. These platforms now handle complex feature engineering, model selection, and hyperparameter tuning with minimal human intervention. In my cancer treatment modeling work, AutoML has reduced our initial model development time from weeks to hours, allowing us to focus on domain-specific optimizations. ...

When I tell people I work on AI for cancer treatment, they often ask: "How accurate are your predictions?" The real question they should be asking is: "How certain is your AI about those predictions?" This distinction lies at the heart of uncertainty quantification (UQ) – a critical but often overlooked aspect of AI research that I believe will define the next generation of trustworthy artificial intelligence systems, especially in healthcare. ...

The convergence of artificial intelligence and healthcare is creating unprecedented opportunities to transform how we treat cancer. As an AI researcher at the University of Birmingham, I'm witnessing firsthand how machine learning algorithms and mathematical models are making personalised medicine a reality rather than a distant promise. The AI Revolution in Treatment Planning Traditional cancer treatment follows a one-size-fits-all approach, but we know that every patient's cancer is unique. AI is changing this paradigm by processing vast amounts of patient data—from genetic profiles to imaging scans—to create individualised treatment strategies. In my research, I develop AI systems that can predict how specific tumours will respond to different therapies, essentially creating a digital twin of each patient's cancer. ...